TruSight Oncology 500 Portfolio
Take cancer from uncertainty to insight
Enabling comprehensive genomic profiling from tissue and liquid biopsies
TruSight Oncology 500 portfolio
The TruSight Oncology 500 portfolio consists of three research assays which enable pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples. The portfolio is designed to identify relevant biomarkers in guidelines and clinical research, such as tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD).
TruSight Oncology 500 Assay
Now with HRD* *Not available in Japan
Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).
TruSight Oncology 500 High-Throughput Assay
Now offered on NextSeq 1000, NextSeq 2000
and NovaSeq X Series
Batch up to 960 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.
TruSight Oncology 500 ctDNA v2 Assay
Now offered on NovaSeq X Series
Analyze circulating tumor DNA (ctDNA) from blood plasma with a more sensitive and streamlined assay in <4 days with automation-friendly options.
Benefits of TruSight Oncology 500 portfolio
Enable comprehensive genomic profiling
Bring the assay into your lab
Integrated, flexible, and scalable workflow
Achieve timely and reliable results
TruSight Oncology 500 portfolio brochure
As an industry leader in NGS with 25+ years of innovation, you can rely on Illumina as your preferred provider of CGP solutions. As a single supplier with expertise across the entire workflow—from library preparation to sequencing through bioinformatics—Illumina can help you efficiently enable CGP in your lab. The Illumina portfolio provides a variety of options tailored to meet the needs of your institution.
Download TSO 500 portfolio brochureTruSight Oncology 500 portfolio news
Learn about portfolio updates that enable a simpler, faster, and more scalable samples-to-results workflow to enable comprehensive genomic profiling in your lab.
HRD assessment
Maximize tumor insights by enabling comprehensive genomic profiling with the added value of homologous recombination deficiency (HRD) assessment. HRD is available for TruSight Oncology 500*.
*Not available in Japan
TruSight Oncology ctDNA v2 on the NovaSeq X Series
See how the performance of the NovaSeq X compares to the NovaSeq 6000 using ctDNA samples with the TruSight Oncology ctDNA v2 assay. Results demonstrate the same high level of performance with significantly reduced run times when using the NovaSeq X Series.
End-to-end solutions for bioinformatics
From wet lab to data insights, Illumina Connected Software offers solutions for every workflow stage of the TruSight Oncology 500 portfolio.
NovaSeq X Series now supported
TruSight Oncology 500 High-Throughput and ctDNA v2 are fully supported on the NovaSeq X Series with the same great performance as the NovaSeq 6000.
Assay comparison
| TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | TruSight Oncology 500 ctDNA v2 |
|---|---|---|
| FFPE (DNA and RNA) | FFPE (DNA and RNA) | Blood (cfDNA) |
| 523 genes for DNA variants | 523 genes for DNA variants | 523 genes for DNA variants |
| 55 genes for RNA fusions and splice variants | 55 genes for RNA fusions and splice variants | 23 genes for DNA fusions |
| Variants called: SNVs InDels CNVs Fusions Splice variants Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology) HRD - Through addition of TSO 500 HRD kit |
Variants called: SNVs InDels CNVs Fusions Splice variants Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology) |
Variants called: SNVs InDels CNVs Fusions (from DNA) Genomic signatures TMB (Immuno-Oncology) MSI (Immuno-Oncology) |
| Panel size: 1.94 Mb DNA; 358 kb RNA |
Panel size: 1.94 Mb DNA; 358 kb RNA |
Panel size: 1.94 Mb DNA |
| Approximate Turnaround Time: 4–5 days |
Approximate Turnaround Time: 4–5 days |
Approximate Turnaround Time: 3-4 days |
| Sequencing Platforms: TSO 500 -- NextSeq 500, NextSeq 550, NextSeq550Dx in Research Mode TSO 500 HRD -- NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000 SP Flow Cell |
Sequencing Platforms: NextSeq 1000 & 2000a NovaSeq 6000 NovaSeq 6000Dx in RUO Mode a NovaSeq X Seriesa |
Sequencing Platforms: NovaSeq 6000 NovaSeq 6000Dx in RUO Mode a NovaSeq X |
| Sample Batching: TSO 500 -- 8 samples/run TSO 500 HRD -- 8-16 samples/run |
Sample Batching: 8-36 samples/run (NextSeq 1000 & 2000) 16–192 samples/run (NovaSeq 6000) 32-480 samples/run (NovaSeq X) 32-960 samples/run (NovaSeq X Plus) |
Sample Batching: 8–48 samples/run |
| Sample input: 40 ng DNA 40 ng RNA |
Sample input: 40 ng DNA 40–80 ng RNA |
Sample input: 20 ng cfDNA (10–30 ng possible) |
| Analytical Specificity: 99.9998% |
Analytical Specificity: 99.9998% |
Analytical Specificity: 99.9994% (SNVs) |
| Analytical Sensitivity: >96% |
Analytical Sensitivity: >96% |
Analytical Sensitivity: >95% |
aRequires a separate, stand-alone DRAGEN server for secondary analysis
Pan-cancer biomarkers
Detection of currently relevant DNA & RNA* variants for multiple types of solid tumors. Some key biomarkers include:
| Pan-cancer: BRAFNTRK1 NTRK2 NTRK3RET MSI TMB | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genes with biomarkers of significance† | Genes with biomarkers of potential significance‡ | ||||||||||
 Breast |
BRCA1 | BRCA2 | ERBB2 | ESR1 | PALB2 | PIK3CA | 180 | ||||
 Colorectal |
ERBB2 | KRAS | NRAS | 166 | |||||||
 Bone |
EGFR | ERG | ETV1 | ETV4 | EWSR1 | FEV | FLI1 | FUS | H3F3A | 140 | |
| HEY1 | IDH1 | MDM2 | NCOA2 | SMARCB1 | |||||||
 Lung |
ALK | EGFR | ERBB2 | KRAS | MET | NUTM1 | ROS1 | 223 | |||
 Melanoma |
KIT | NRAS | ROS1 | 172 | |||||||
 Ovarian |
BRCA1 | BRCA2 | FOXL2 | 149 | |||||||
 CNS |
APC | ATRX | CDKN2A | CDKN2B | EGFR | H3F3A | HIST1H3B | HIST1H3C | IDH1 | 140 | |
| IDH2 | MYCN | PTCH1 | RELA | TERT | TP53 | ||||||
 Prostate |
AR | ATM | BARD1 | BRCA1 | BRCA2 | BRIP1 | CDK12 | CHEK1 | CHEK2 | 151 | |
| FANCL | FGFR2 | FGFR3 | PALB2 | RAD51B | RAD51C | RAD51D | RAD54L | ||||
 Thyroid |
HRAS | KRAS | NRAS | RET | TERT | 165 | |||||
 Uterine & cervical |
BRCA2 | EPC1 | ERBB2 | ESR1 | FOXO1 | GREB1 | JAZF1 | NCOA2 | NCOA3 | 138 | |
| NUTM2A | NUTM2B | PAX3 | PAX7 | PHF1 | POLE | SMARCA4 | SUZ12 | TP53 | |||
| YWHAE | |||||||||||
 Other Solid Tumors |
ALK | APC | ARID1A | ASPSCR1 | ATF1 | ATIC | BAP1 | BCOR | BRCA1 | 152 | |
| BRCA2 | CAMTA1 | CARS | CCNB2 | CDK4 | CDKN2A | CIC | CITED2 | CLTC | |||
| COL1A1 | COL6A3 | CREB1 | CREB3L1 | CREB3L2 | CSF1 | CTNNB1 | DDIT3 | DDX3X | |||
| DNAJB1 | DUX4 | EED | EGFR | ERBB2 | ERG | ETV1 | ETV4 | ETV6 | |||
| EWSR1 | FEV | FGFR2 | FGFR3 | FLI1 | FOXL2 | FOXO1 | FOXO4 | FUS | |||
| GLI1 | HEY1 | HGF | HMGA2 | IDH1 | KRAS | LEUTX | MAML3 | MDM2 | |||
| MYB | MYOD1 | NAB2 | NCOA2 | NF1 | NFATC2 | NFIB | NR4A3 | NRAS | |||
| NUTMI | NUTM2A | NUTM2B | PALB2 | PATZ1 | PAX3 | PAX7 | PDGFB | PDGFRA | |||
| PRKACA | PRKD1 | RANBP2 | ROS1 | SDHA | SDHB | SDHC | SDHD | SMARCB1 | |||
| SS18 | SSX1 | SSX2 | SSX4 | STAT6 | SUZ12 | TAF15 | TCF12 | TERT | |||
| TFE3 | TFEB | TFG | TP53 | TPM3 | TPM4 | TRAF7 | TSPAN31 | VGLL2 | |||
| WT1 | WWTR1 | YAP1 | YWHAE | ZC3H7B | |||||||
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.
* RNA variants only called from TSO 500 and TSO 500 HT assays.
† The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.
Analytical evaluation guidance
The TruSight Oncology 500 analytical guidance expedites implementation with recommendations intended to align with the latest industry standards and best practices.
View guidanceTruSight Oncology 500 portfolio resources
TruSight Oncology ctDNA 500 v2
Illumina has improved the analysis of solid tumors from circulating tumor DNA (ctDNA) with TruSight Oncology 500 ctDNA v2. Learn about the new features and benefits in the video.
Research collaboration with Nation Center Japan
TruSight Oncology 500 ctDNA panel to be used for research into personalized cancer treatments for nasopharyngeal carcinoma.
TruSight Oncology 500 High-Throughput on the NovaSeq X Series
Learn how the power of the NovaSeq X Series can enable reliable comprehensive genomic profiling with the same great performance as the NovaSeq 6000.
TruSight Oncology 500 HRD
Homologous recombination deficiency (HRD) is an important biomarker in ovarian cancer. Hear about TSO 500 HRD assay performance from Dr. Guillaume Bataillon at the Oncopole Toulouse laboratory in France.